Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Adial Pharmaceuticals, Inc. WT EXP 073123 ADILW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $8M (loss), growing at -1.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $5M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 4.42 (strong liquidity). Debt-to-assets is 0%. Total assets: $7M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

ADILW SharesGrow Score Overview

48/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ADILW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ADILW: +0%/yr revenue is, -1.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ADILW: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 4.42 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ADILW: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range9.0E-4-0.0025
Volume5.18K
Beta (1Y)0.00
Share Statistics
EPS (TTM)-11.93
Shares Outstanding$668.63K
IPO Date2018-07-27
CEONone
Financial Highlights & Ratios
Gross Profit$-565.00
EBITDA$-7.8M
Net Income$-7.98M
Operating Income$-7.8M
Total Cash$5.88M
Net Debt$-5.88M
Total Assets$6.67M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD

Price Chart

Track all markets on TradingView
ADILW
Adial Pharmaceuticals, Inc. WT EXP 073123  ·  NASDAQ Capital Marke
Healthcare • Biotechnology

People Also View

IMACW
IMACW
IMAC Holdings, Inc.
$0.01
+10.09%
 ARTLW
ARTLW
Artelo Biosciences, Inc.
$0.01
+0.00%
 BCDAW
BCDAW
BioCardia, Inc.
$0.01
-3.17%
 CREXW
CREXW
Creative Realities, Inc. WT EXP 110922
$0.00
+6.98%
 ENTXW
ENTXW
Entera Bio Ltd. WT EXP 062723
$0.00
-60.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message